Advertisement

PharmacoEconomics

, Volume 36, Issue 10, pp 1143–1151 | Cite as

Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

  • Rachid Rafia
  • Abdullah Pandor
  • Sarah Davis
  • John W. Stevens
  • Sue Harnan
  • Mark Clowes
  • Youssef Sorour
  • Robert Cutting
Review Article

Abstract

As part of its single technology appraisal process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of obinutuzumab (Roche) to submit evidence on its clinical and cost effectiveness when used in combination with bendamustine in patients with follicular lymphoma (FL) refractory to rituximab. The Evidence Review Group (ERG), the School of Health and Related Research Technology Appraisal Group at the University of Sheffield, produced a document summarising the key points from the company submission alongside a critical review. Efficacy for progression-free survival (PFS) and safety was positively demonstrated in the pivotal GADOLIN trial, which compared obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance (O-Benda+O) against bendamustine monotherapy. Data on overall survival were immature. The company submitted a model-based economic analysis, including a patient access scheme. The ERG identified a number of limitations, in particular the absence of subgroup analysis and the approach used by the company to estimate overall survival (OS), which was more favourable to the intervention arm. The key uncertainty was the duration of the treatment effect on OS. This uncertainty is expected to be reduced when the final analysis of the GADOLIN trial is reported. Consequently, the NICE appraisal committee recommended O-Benda+O in the population covered by the marketing authorisation within the Cancer Drug Fund until NICE is able to review the guidance following publication of the final analysis of GADOLIN.

Notes

Acknowledgements

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (project number 14/177/09 STA). See the HTA programme website for further project information (http://www.hta.ac.uk). This summary of the ERG report was compiled after NICE issued guidance. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of NICE or the Department of Health. The authors also wish to thank Dr. Andrew McMillan for providing clinical advice and commenting on draft materials during the project. This summary was externally reviewed by PharmacoEconomics.

Author contributions

RR, AP, SD drafted the manuscript and take responsibility as guarantors of the content. JWS, SH, MC, YS and RC revised the manuscript for important intellectual content or provided comments. All authors have given their approval for the final version to be published.

Compliance with Ethical Standards

Funding

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (project number 14/177/09 STA). See the HTA programme website for further project information (http://www.hta.ac.uk).

Conflicts of Interest

RR, AP, SD, JWS, SH, MC, YS and RC have no conflicts of interest.

References

  1. 1.
    National Institute for Health and Care Excellence, Guide to the methods of technology appraisal. London UK, 2013: Available at: https://www.nice.org.uk/article/pmg9/ [Last accessed 07 March 2018].
  2. 2.
    Rafia R, P.A., Stevens J, Harnan S, Davis S, Clowes M, McMillan A, Sorour Y, Cutting R, Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma: a single technology appraisal. School of Health and Related Research (ScHARR), 2016: Available at: https://www.nice.org.uk/guidance/ta472/documents/appraisal-consultation-document-2 [Last acessed 07 March 2018].
  3. 3.
    National Institute for Health and Care Excellence, Final appraisal determination: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab. London UK, 2016: Available at: https://www.nice.org.uk/guidance/ta472/documents/final-appraisal-determination-document [Last accessed 07 March 2018].
  4. 4.
    National Institute for Health and Care Excellence, Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab; Technology appraisal guidance [TA472]. London UK, 2017: Available at: https://www.nice.org.uk/guidance/ta472/history [Last accessed 07 March 2018].
  5. 5.
    National Institute for Health and Care Excellence, Non-Hodgkin’s lymphoma: diagnosis and management: NICE guideline [NG52]. London UK, 2016: Available at: https://www.nice.org.uk/guidance/ng52 [Last accessed 07 March 2018].
  6. 6.
    Roche Products Limited, Gazyvaro▼ (obinutuzumab) in combination with bendamustine for treating rituximab-refractory follicular lymphoma. Company evidence submission to NICE, 2016: Available at: https://www.nice.org.uk/guidance/ta472/documents/appraisal-consultation-document-2 [Last acessed 07 March 2018].
  7. 7.
    Roche Products Limited, ID841 Gazyvaro (obinutuzumab) with bendamustine for treating follicular lymphoma refractory to rituximab - Response to ACD. 2016, National Institute for Health and Care Excellence: London UK. Available at: https://www.nice.org.uk/guidance/ta472/documents/appraisal-consultation-document-2 [Last acessed 07 March 2018].
  8. 8.
    Roche Products Ltd, Gazyvaro▼ (obinutuzumab) in combination with bendamustine for treating rituximab-refractory follicular lymphoma: Response to clarification. 2016: Available at: https://www.nice.org.uk/guidance/ta472/documents/appraisal-consultation-document-2 [Last acessed 07 March 2018].
  9. 9.
    Cheson B. et al. GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. In: 13th International Conference on Malignant Lymphoma, 2015: Abstract 123.Google Scholar
  10. 10.
    Sehn L, et al. GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. J Clin Oncol. 2015;33:8502 (ASCO Annual Meeting).CrossRefGoogle Scholar
  11. 11.
    Pott C. et al. Analysis of minimal residual disease in follicular lymphoma patients in GADOLIN, a Phase III study of obinutuzumab plus bendamustine versus bendamustine in relapsed/refractory indolent non-Hodgkin lymphoma. In: ASH 57th Annual Meeting and Exposition. 2015: Orlando, Florida. Abstract 3978Google Scholar
  12. 12.
    Cheson B et al Primary results of the health-related quality of life assessment from the Phase III GADOLIN study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory, indolent non-Hodgkin lymphoma. In: ASH 57th Annual Meeting and Exposition. 2015: Orlando, Florida. Abstract 1523.Google Scholar
  13. 13.
    F. Hoffmann-La Roche Ltd, Primary Clinical Study Report—GAO4753g/GO01297—An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin’s lymphoma. Clinical Study Report—1051204. July 2015.Google Scholar
  14. 14.
    F. Hoffmann-La Roche Ltd, Update Clinical Study Report—GAO4753g/GO01297—An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximabrefractory, indolent non-Hodgkin lymphoma. Report No. 1067639. December 2015.Google Scholar
  15. 15.
    National Institute for Health and Care Excellence, Final Scope: Obinutuzumab in combination with bendamustine for treating rituximabrefractory follicular lymphoma. London, UK, 2016: Avaialble at: https://www.nice.org.uk/guidance/ta472/documents/final-scope [Last accessed 07 March 2018].
  16. 16.
    Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration. US: Wiley; 2011. http://handbook.cochrane.org.
  17. 17.
    Schulz KF, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Juni P, et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054–60.CrossRefPubMedGoogle Scholar
  19. 19.
    Brookes S, et al. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5(33):1–56.CrossRefPubMedGoogle Scholar
  20. 20.
    Hamlin PA. Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma. Lancet Oncol. 2016.  https://doi.org/10.1016/S1470-2045(16)30157-7.PubMedGoogle Scholar
  21. 21.
    Wild D, Pettengell R, Walker M, et al. Utility elicitation in patients with follicular lymphoma. Value Health. 2006;9(6):A294.CrossRefGoogle Scholar
  22. 22.
    Papaioannou D, Rafia R, Rathbone J, Stevenson M, Woods HB, Stevens J. Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of technology appraisal no. 110): a systematic review and economic evaluation. Health Technol Assess. 2012;16(37):1–253, iii–iv.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR)University of SheffieldSheffieldUK
  2. 2.Consultant in HaematologyBarnsley Hospitals NHS TrustBarnsleyUK

Personalised recommendations